AstraZeneca PLC shares are trading lower after the company announced that Datopotamab deruxtecan did not reach statistical significance and did not show an overall survival improvement.
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca PLC shares declined after the company reported that its drug, Datopotamab deruxtecan, failed to achieve statistical significance and did not show an improvement in overall survival.
September 09, 2024 | 6:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AstraZeneca's shares dropped following the announcement that its drug, Datopotamab deruxtecan, did not meet statistical significance or show overall survival improvement in trials.
The failure of Datopotamab deruxtecan to meet key trial endpoints is a significant setback for AstraZeneca, likely leading to a negative investor sentiment and a short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100